People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| IconOVir Bio, Inc. | — | Biotechnology | Series C | $97.2M | $271.4M | 2023 |
Heba M. Nowyhed at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Heba M. Nowyhed on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joshua A. Kazam | 1 | 10 |
| David M. Tanen | 1 | 8 |
| Helen S. Kim | 1 | 6 |
| Arie S. Belldegrun | 1 | 5 |
| Sean A. Algeo | 1 | 2 |
| Mark A. McCamish | 1 | 2 |
| Jakob S. Loven | 1 | 2 |
| Sean M. Algeo | 1 | 1 |
| Jakob A. Loven | 1 | 1 |
| Nicole M. Van De Leuv | 1 | 1 |
| David A. Chang | 1 | 1 |
| William S. Kaelin | 1 | 1 |
| Julie A. Maltzman | 1 | 1 |
| John A. Huynh | 1 | 1 |
| David S. Chang | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.